TerrAscend Corp. (TSX: TSND) will release its financial results for the third quarter ended September 30, 2026, on November 5, 2026. The company plans to host a conference call at 5:00 pm Eastern Time the same day to discuss the performance.

Conference Call Details

The earnings call will take place following the market close on November 5. Investors can access the webcast or dial in using the provided numbers. A replay will be available for two weeks.

Regulatory Context and Operations

TerrAscend operates across North America, including Pennsylvania, New Jersey, Maryland, Ohio, and California. The company owns brands such as The Apothecarium, Cookies, and Kind Tree.

The announcement follows a significant regulatory shift in the United States. On April 23, 2026, the US Department of Justice issued a final rule rescheduling marijuana contained in FDA-approved drug products and marijuana subject to state medical licenses from Schedule I to Schedule III of the Controlled Substances Act. This rule became effective on April 28, 2026.

Despite this change, the company notes that marijuana not falling under these specific categories remains a Schedule I controlled substance. Strict compliance with state laws does not absolve liability under US federal law. Financial transactions involving cannabis proceeds may still face scrutiny under federal money laundering legislation.

TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) has closed its acquisition of Aunt Mary’s Dispensary LLC, marking its fifth retail location in New Jersey.

The transaction strengthens the company’s presence in the state with a dispensary that generates over US$10 million in annualized revenue. Management stated the addition is immediately accretive to EBITDA and free cash flow.

Deal Structure and Terms

TerrAscend entered into the agreement in June 2026 for total consideration of US$9 million. The payment structure involves two components:

• US$3 million via a five-year unsecured convertible debenture bearing interest at 6.0% per annum. This instrument grants an option to purchase 35% of Aunt Mary’s.
• US$6 million payable in cash upon exercise of that option.

Jason Wild, Executive Chairman of TerrAscend, noted opportunities to enhance sales through the integration of the company’s premium brand portfolio. "We are excited to welcome the Aunt Mary’s team to the TerrAscend family," Wild said.

Regulatory and Operational Context

The transaction aligns with New Jersey’s regulatory framework for diversely owned businesses. Upon exercise of the option and satisfaction of additional conditions, TerrAscend will fully consolidate the business in its financial results.

This move increases TerrAscend’s consolidated retail footprint to a total of 21 dispensaries across five U.S. states and Canada. The company operates in Pennsylvania, New Jersey, Maryland, Ohio, and California, alongside Canadian retail operations.

What the Numbers Show

The deal structure highlights a strategic use of convertible debt to fund expansion while preserving immediate liquidity. By structuring US$3 million of the US$9 million consideration as a convertible debenture rather than immediate cash, TerrAscend delays a significant portion of the outflow until the option is exercised. This approach allows the company to capture the accretive EBITDA and cash flow from the US$10 million revenue-generating asset upfront, while deferring the bulk of the equity purchase cost.

Legal and Forward-Looking Disclosures

Investors are reminded of significant legal restrictions governing U.S. cannabis operations. On April 23, 2026, the U.S. Department of Justice issued a final rule rescheduling marijuana in FDA-approved drug products and state medical marijuana from Schedule I to Schedule III of the Controlled Substances Act. This rule became effective on April 28, 2026.

However, other forms of marijuana remain Schedule I controlled substances under federal law. TerrAscend noted that strict compliance with state laws does not absolve liability under U.S. federal law. Enforcement of federal laws remains a significant risk to the company’s business and financial performance.

The press release contains forward-looking statements regarding expected benefits, including anticipated EBITDA and free cash flow accretion. These statements are subject to risks such as integration challenges, regulatory changes, and market conditions.